BerGenBio ASA: Approval and publication of prospectus for the preferential Rights Issue
Retrieved on:
Friday, May 26, 2023
BERGEN, Norway, May 26, 2023 /PRNewswire/ -- Reference is made to the stock exchange announcement by BerGenBio ASA (the "Company") on 22 May 2023 regarding approval by the Company's annual general meeting of a partially underwritten rights issue in the Company to raise gross proceeds of up to NOK 250 million (the "Rights Issue"), and the issuance of warrants to subscribers in the Rights Issue (the "Warrants").
Key Points:
- THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.
- The Financial Supervisory Authority of Norway (Nw: Finanstilsynet) has today, 26 May 2023, approved a prospectus prepared by the Company in connection with the Rights Issue (the "Prospectus") and the listing of between 1,687,500,000 and 2,500,000,000 offer shares in the Rights Issue.
- Advisers: Carnegie AS and Arcitc Securites AS have been retained by the Company to act as managers for the Rights Issue.
- Advokatfirmaet Thommessen AS is acting as legal adviser to the Company in connection with the Rights Issue.